Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-06-17
2008-06-17
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S183000
Reexamination Certificate
active
07388009
ABSTRACT:
Compounds having the formula (I),and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R1, R2, R3, R4, R5, R6, X and Z are as described in the specification.
REFERENCES:
patent: 6147080 (2000-11-01), Bemis et al.
patent: 6277989 (2001-08-01), Chakravarty et al.
patent: 2003/0069244 (2003-04-01), Leftheris et al.
patent: 2003/0186983 (2003-10-01), Mastalerz et al.
patent: WO 00/56738 (2000-09-01), None
patent: WO 00/71129 (2000-11-01), None
patent: WO 01/14378 (2001-03-01), None
patent: WO 01/27089 (2001-04-01), None
patent: WO 01/34605 (2001-05-01), None
patent: WO 02/40486 (2002-05-01), None
patent: WO 03/091229 (2003-06-01), None
patent: WO 2004/043912 (2004-05-01), None
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
,Rankin et al., Br. J. Rheumatol. vol. 34, 334-342, 1995.
Moreland et al., Ann Intern, Med., vol. 130, 478-486, 1999.
Henry et al., Drugs. Fut., vol. 24, pp. 1345-1354 (1999).
U.S. Appl. No. 10/623,171, filed Jul. 18, 2003, Bhide et al.
U.S. Appl. No. 10/633,997, filed Aug. 4, 2003, Bhide et al.
Branger, J., et al., “Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia”, The Journal of Immunology, vol. 168, pp. 4070-4077, (2002).
Davis, J. C., Jr., “Understanding the Role of Tumor Necrosis Factor Inhibition in Ankylosing Spondylitis”, Seminars in Arthritis and Rheumatism, vol. 34, pp. 668-677, (2004).
Gottlieb, A. B., et al., TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques1, The Journal of Immunology, vol. 175, pp. 2721-2729, (2005).
Hideshima, T. et al, “Targeting p38 MAPK Inhibits multiple myeloma cell growth in the bone marrow milleu”, Blood, vol. 101(2), pp. 703-706, (2003).
Johansen, C., et al., “Protein Expression of TNF-α in Psoriatic Skin Is Regulated at a Posttrancriptional Level by MAPK-Activated Protein Kinase 21”, The Journal of Immunology, vol. 176, pp. 1431-1438, (2006).
Johansen, C., et al., “The mitogen-activated protein kinases p38 and KRK1/2 are increased in lesional psoriatic skin”, British Journal of Dermatology, vol. 152, pp. 37-42, (2005).
Kumar, S., et al., “P38 MAP Kinaes: Key Signalling Molecules as Therapeutic Targets for Inflammatory Diseases”, vol. 2, pp. 717-726, (2003).
Mease, P. J. et al., “Psoriatic arthritis treatment: biological response modifiers”, Ann. Rheum. Dis., vol. 64 (Suppl. II), pp. ii78-ii82, (2005).
Navas, TA, et al., Inhibition of p38α MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-XL, MCI-1 and p53 levels in vitro and inhibits tumor growth in vivo, Leukemia, 1-11 (2006).
Papp, K. A., “The long-term efficacy and safety of new biological therapies for psoriasis”, Arch. Dermatol. Res. vol. 298, pp. 7-15, (2006).
Saklatvala, J., “The p38 MAP kinase pathway as a therapeutic target in inflammatory disease”, Current Opinion in Pharmacology, vol. 4, pp. 372-377, (2004).
Waetzig G. H., “p38 Mitogen-Activated Protein Kinase Is Activated and Linked to TNF-α Signaling in Inflammatory Bowel Disease1”, The Journal of Immunology, vol. 168, pp. 5342-5351, (2002).
Dyckman Alaric J.
Leftheris Katerina
Wrobleski Stephen T.
Balasubramanian Venkataraman
Bristol--Myers Squibb Company
Wang Joseph C.
Winslow Anastasia P.
LandOfFree
Heteroaryl-substituted pyrrolo-triazine compounds useful as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl-substituted pyrrolo-triazine compounds useful as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl-substituted pyrrolo-triazine compounds useful as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2803848